-
Immune tolerance induction in the era of emicizumab - still the first choice for patients with hemophilia A and inhibitors
Speaker(s): Dr. Katharina Holstein
NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn about the latest in research, breakthrough developments, and more.